Kazutaka Narui

Yokohama, Japan

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 99 publications

ASO Visual Abstract: A Neuron Projection Guidance Signature Associates With Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer.

ASO Visual Abstract: A Neuron Projection Guidance Signature Associates With Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer.

Journal: Annals of surgical oncology

Published: August 06, 2026

Association of tumor Schwann cells with epithelial-mesenchymal transition and immune-suppressive microenvironment in triple-negative breast cancer.

Association of tumor Schwann cells with epithelial-mesenchymal transition and immune-suppressive microenvironment in triple-negative breast cancer.

Journal: Breast cancer research and treatment

Published: June 12, 2026

ASO Author Reflections: Neuron Projection Guidance-A transcriptomic perspective on tumor-induced neural recruitment in breast cancer.

ASO Author Reflections: Neuron Projection Guidance-A transcriptomic perspective on tumor-induced neural recruitment in breast cancer.

Journal: Annals of surgical oncology

Published: June 08, 2026

The development of Breast Apocrine Carcinoma (BAC) score that distinguishes breast and cutaneous apocrine carcinomas.

The development of Breast Apocrine Carcinoma (BAC) score that distinguishes breast and cutaneous apocrine carcinomas.

Journal: Research square

Published: June 05, 2026

The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status.

The clinical relevance of apocrine morphology in breast cancer depends on the estrogen receptor status.

Journal: NPJ breast cancer

Published: March 04, 2026

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Abemaciclib plus endocrine therapy in chemotherapy-treated patients with hormone receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer.

Journal: Breast cancer (Tokyo, Japan)

Published: February 12, 2026

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.

Real-world data for a CDK4/6 inhibitor, palbociclib, as 1st- or 2nd-line therapy in HR+/HER2- metastatic breast cancer: a multicenter prospective cohort study.

Journal: Breast cancer research : BCR

Published: February 02, 2026

A Neuron Projection Guidance Signature Associates with Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer.

A Neuron Projection Guidance Signature Associates with Immune-Cold Tumor Microenvironment and Poor Outcomes in Breast Cancer.

Journal: Annals of surgical oncology

Published: January 23, 2026

Clinicopathological predictors of distant recurrence in breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy.

Clinicopathological predictors of distant recurrence in breast cancer patients achieving pathological complete response after neoadjuvant chemotherapy.

Journal: European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology

Published: January 10, 2026

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.

TP53 mutation is associated with shorter treatment duration with CDK4/6 inhibitors, but not with immune checkpoint inhibitors, in ER-positive/HER2-negative breast cancer: real-world perspective.

Journal: Breast cancer research : BCR

Published: November 11, 2025

Multidimensional impact of fixed-dose subcutaneous trastuzumab-pertuzumab on oncology workflow and patient time burden in a real-world study.

Multidimensional impact of fixed-dose subcutaneous trastuzumab-pertuzumab on oncology workflow and patient time burden in a real-world study.

Journal: Breast cancer (Tokyo, Japan)

Published: September 30, 2025

Organ-Specific Clinicopathological Features That Are Associated With Post-Relapse Survival of Metastatic Breast Cancer in Japanese Women: A Multicenter Cohort Study.

Organ-Specific Clinicopathological Features That Are Associated With Post-Relapse Survival of Metastatic Breast Cancer in Japanese Women: A Multicenter Cohort Study.

Journal: World journal of oncology

Published: August 27, 2025

Showing 1-12 of 99

Last Updated: 09/26/2026